Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcutis Biotherapeutics Inc
(NQ:
ARQT
)
9.830
+1.510 (+18.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Arcutis Biotherapeutics Inc
< Previous
1
2
3
Next >
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
July 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) Leading the Way in Friday Trading Based on Percentage Gain
February 09, 2024
Via
Investor Brand Network
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
July 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
July 23, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
July 22, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
July 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
July 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
June 10, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
June 05, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
May 13, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Appoints David Topper as Chief Financial Officer
April 10, 2024
Industry veteran with over 40 years of experience in finance, investment management, and investment banking
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
March 11, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
March 10, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
March 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
March 04, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
March 04, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Pricing of $150 Million Public Offering
February 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Proposed Public Offering
February 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
February 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
January 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
January 22, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
January 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
January 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) is One of Monday Morning’s Most Active Stocks
December 18, 2023
Via
Investor Brand Network
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
December 15, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.